Commitments and Contingent Liabilities (Details) $ in Thousands |
1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 01, 2020 |
Apr. 30, 2019 |
Dec. 31, 2017
USD ($)
|
May 31, 2017
USD ($)
shares
|
Sep. 30, 2015
USD ($)
|
Sep. 30, 2020
USD ($)
shares
|
Sep. 30, 2020
ILS (₪)
shares
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2019
ILS (₪)
|
Dec. 31, 2017
USD ($)
|
Sep. 30, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
|
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Approved budget | $ 726 | |||||||||||
| Percentage of approved budget | 85.00% | 85.00% | 30.00% | 30.00% | ||||||||
| Contingent obligation | $ 701 | $ 585 | $ 909 | $ 889 | ||||||||
| New application of total budget amount | $ 3,100 | |||||||||||
| Other commitments, description | The program is for the period beginning January 2020 through December 2020. | The program is for the period beginning January 2020 through December 2020. | The program is for the period beginning July 2019 through December 2019. | The program is for the period beginning July 2019 through December 2019. | ||||||||
| Amount of liabilities recorded to agreement | $ 378 | $ 217 | ||||||||||
| Research collaboration agreement, description | BiomX Israel entered into a research collaboration agreement with Boehringer Ingelheim International GmbH ("BI") for a collaboration on biomarker discovery for IBD. Under the agreement, BiomX Israel is eligible to receive fees totaling $439 in installments of $50 within 60 days of the Effective date, $100 upon receipt of the BI materials, $150 upon the completion of data processing and $139 upon delivery of the Final Report of observations and Results of the Project (as such terms are defined within the agreement). Unless terminated earlier, this agreement will remain in effect, until one year after the Effective Date or completion of the Project Plan (as defined in the agreement) and submission and approval of the Final Report. The research period started during September 2020. | |||||||||||
| Contingent obligation to IIA | 2,300 | |||||||||||
| License Agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Approved budget | $ 1,800 | |||||||||||
| Annual license fees | $ 10 | |||||||||||
| NIS [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Approved budget | ₪ | ₪ 2,700 | |||||||||||
| New application of total budget amount | ₪ | ₪ 10,800 | |||||||||||
| 2017 License Agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Consideration percentage | 1.00% | |||||||||||
| Annual license fees | $ 10 | 10 | ||||||||||
| Warrants to purchase ordinary shares | shares | 591,382 | |||||||||||
| Additional Application [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Additional budget | $ 500 | $ 4,400 | ||||||||||
| Commitments and Contingent Liabilities, description | (i) to pay a license issue fee of $20 and annual license fees ranging from $15 to $25 and (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 thousand and (iii) make tiered royalty payments, in the low single digits based on future revenue. The condensed consolidated financial statements include liabilities with respect to this agreement in the amount of $378 and $217 as of September 30, 2020 and December 31, 2019, respectively. | The Company will pay an annual license fee of between $15 and $25 subject to the terms and conditions specified in the agreement. Additionally, the Company is obligated to make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $3.2 thousand and royalty payments based on future revenue. As the Company has not yet generated revenue from operations and the achievement of certain milestones is not probable, no provision was included in the condensed consolidated financial statements as of September 30, 2020 and December 31, 2019 with respect to the agreement. | ||||||||||
| Budget percentage | 30.00% | |||||||||||
| Additional Application [Member] | NIS [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Additional budget | ₪ | ₪ 1,600 | ₪ 15,600 | ||||||||||
| Maximum [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Royalties rate | 3.50% | 3.50% | ||||||||||
| Annual license fees | $ 25 | |||||||||||
| Minimum [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Royalties rate | 3.00% | 3.00% | ||||||||||
| Annual license fees | $ 15 | |||||||||||
| Loan Agreements [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Outstanding balance of the loan | $ 19 | |||||||||||
| Aggregate amount of the remaining potential commitment | 83 | $ 260 | ||||||||||
| Loan granted | $ 19 | |||||||||||
| Number of common stocks granted | shares | 5,700 | 5,700 | ||||||||||
| Patent License Agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Other commitments, description | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $4.7 thousand in aggregate, as well as royalty payments on future revenues. | BiomX Israel is also required to make payments to MIT upon the satisfaction of development and commercialization milestones totaling up to $4.7 thousand in aggregate, as well as royalty payments on future revenues. | ||||||||||
| Annual license fees | $ 25 | |||||||||||
| Maximum payments of license maintenance fees | $ 250 | |||||||||||
| Amount of liabilities recorded to agreement | $ 240 | $ 108 | ||||||||||
| Party to a license agreement [Member] | ||||||||||||
| Commitments and Contingent Liabilities (Textual) | ||||||||||||
| Other commitments, description | The condensed consolidated financial statements as of September 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $83 and $260, respectively. | The condensed consolidated financial statements as of September 30, 2020 and December 31, 2019 include a liability with respect to this agreement in the amount of $83 and $260, respectively. | ||||||||||